Drug-induced liver injury, what's new?

Michel Biour

doi:10.1684/hpg.2011.0637



Printable version
Drug-induced liver injury, what's new?
Hépato-Gastro. Volume 18, Number 5, 480-4, Septembre-Octobre 2011, Séminaire SNFGE 2011
Résumé Texte intégral
Author(s) : Michel Biour
Summary : From September 2010, 38 new drugs and 674 references have been included in Hepatox ^®, a bibliographic database on drug-induced liver injury (DILI). DILI remains the main cause for drug withdrawal by health authorities. So recently, gemtozumab-ozogamicin, ketoconazole, sitaxentan and stavudine were withdrawn from the market due to liver injury. The summaries of product characteristics of nimesulide, nitrofurantoin and paracetamol were modified for reducing the occurrence of DILI. Agomelatin, dronedarone and oxaliplatin were suspected of DILI. Numerous drugs like antiepileptics induce hypersensitivity syndrome related to virus reactivation. This syndrome is frequently associated with liver injury. Reporting DILI to health authorities is essential for drug policy.
Keywords : pharmacovigilance, drug-induced liver injury, drug, toxicity